Prof Xavier Leleu speaks to ecancer at the 2019 MyKE Myeloma meeting in Barcelona about the types of topics that were presented on the second day of this meeting.
He explains what will be discussed in tomorrow's session, including a debate about the use of all available drugs to cure multiple myeloma versus the use of sequential treatment.
Prof Leleu also discusses the clinical management of lenalidomide-refractory disease, where subsequent lines of therapy could be affected.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.